🔎 Trials Near Me

Utama › HPV › Ohio

Kajian klinikal HPV di Ohio

6 kajian untuk HPV sedang mencari peserta di lokasi di Ohio.

Teks kajian rasmi (Bahasa Inggeris)

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 25 ke atas · Wanita · Dikemas kini 31 Jul 2026 · NCT07281430

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

  • Planned Parenthood of Greater Ohio (PPGOH), Akron
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 25 ke atas · Wanita · Dikemas kini 24 Jul 2026 · NCT07281599

Zopa Retreatment and Vector Shedding in Adults With RRP

  • University of Cincinnati, Cincinnati
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06538480

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

  • Cleveland Clinic Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Hillcrest Hospital, Mayfield Heights
Mengambil pesertaFasa 2
Umur 25 hingga 100 · Wanita · Dikemas kini 2 Okt 2025 · NCT04098744

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

  • Cleveland Clinic Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Hillcrest Hospital, Mayfield Heights
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 14 Ogo 2025 · NCT06075264

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.